Cargando…

The clinical prognostic significance of ezrin in patients with bone and soft tissue sarcomas: a meta‐analysis

Ezrin is a member of the ezrin–radixin–moesin (ERM) protein family and has been shown to be associated with poor prognosis in patients with a variety of solid tumors. However, the clinical prognostic significance of ezrin in patients with bone and soft tissue sarcomas remains unclear. Here, we perfo...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Feng, Yu, Tao, Ma, Chengbin, Zhang, Haifei, Zhang, Zhiyu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6768105/
https://www.ncbi.nlm.nih.gov/pubmed/31376222
http://dx.doi.org/10.1002/2211-5463.12713
_version_ 1783455053760167936
author Wang, Feng
Yu, Tao
Ma, Chengbin
Zhang, Haifei
Zhang, Zhiyu
author_facet Wang, Feng
Yu, Tao
Ma, Chengbin
Zhang, Haifei
Zhang, Zhiyu
author_sort Wang, Feng
collection PubMed
description Ezrin is a member of the ezrin–radixin–moesin (ERM) protein family and has been shown to be associated with poor prognosis in patients with a variety of solid tumors. However, the clinical prognostic significance of ezrin in patients with bone and soft tissue sarcomas remains unclear. Here, we performed a systematic meta‐analysis by searching PubMed, the Cochrane Library Database, EMBASE, the Web of Science, and the CBM, WanFang Med Online and CNKI databases. In total, 19 studies with a total of 1316 bone and soft tissue sarcoma patients were included. Pooled analyses showed that ezrin overexpression was correlated with a higher rate of tumor metastasis (OR 6.59, 95% CI: 2.84–15.33, P < 0.01, P (FDR) < 0.01) and recurrence (OR 3.18, 95% CI: 1.88–5.37, P < 0.01, P (FDR) < 0.01) and a more advanced tumor grade (OR 3.252, 95% CI: 1.371–7.715, P = 0.01, P (FDR) = 0.03). Moreover, elevated ezrin expression could predict poor OS (HR 3.02, 95% CI: 2.35–3.89, P < 0.01, P (FDR) < 0.01), MFS (HR 5.22, 95% CI: 2.08–13.08, P < 0.01, P (FDR) < 0.01), and EFS (HR 1.07, 95% CI: 1.03–1.11, P < 0.01, P (FDR) < 0.01). Subgroup analyses revealed the underlying sources of heterogeneity. Publication bias was observed in the analysis of metastasis. Sensitivity analysis revealed that the results were robust. Our findings indicated that ezrin overexpression was significantly correlated with poor survival and more advanced tumor progression in bone and soft tissue sarcomas, which suggests that ezrin might be a valuable prognostic biomarker and a potential therapeutic target.
format Online
Article
Text
id pubmed-6768105
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-67681052019-10-01 The clinical prognostic significance of ezrin in patients with bone and soft tissue sarcomas: a meta‐analysis Wang, Feng Yu, Tao Ma, Chengbin Zhang, Haifei Zhang, Zhiyu FEBS Open Bio Research Articles Ezrin is a member of the ezrin–radixin–moesin (ERM) protein family and has been shown to be associated with poor prognosis in patients with a variety of solid tumors. However, the clinical prognostic significance of ezrin in patients with bone and soft tissue sarcomas remains unclear. Here, we performed a systematic meta‐analysis by searching PubMed, the Cochrane Library Database, EMBASE, the Web of Science, and the CBM, WanFang Med Online and CNKI databases. In total, 19 studies with a total of 1316 bone and soft tissue sarcoma patients were included. Pooled analyses showed that ezrin overexpression was correlated with a higher rate of tumor metastasis (OR 6.59, 95% CI: 2.84–15.33, P < 0.01, P (FDR) < 0.01) and recurrence (OR 3.18, 95% CI: 1.88–5.37, P < 0.01, P (FDR) < 0.01) and a more advanced tumor grade (OR 3.252, 95% CI: 1.371–7.715, P = 0.01, P (FDR) = 0.03). Moreover, elevated ezrin expression could predict poor OS (HR 3.02, 95% CI: 2.35–3.89, P < 0.01, P (FDR) < 0.01), MFS (HR 5.22, 95% CI: 2.08–13.08, P < 0.01, P (FDR) < 0.01), and EFS (HR 1.07, 95% CI: 1.03–1.11, P < 0.01, P (FDR) < 0.01). Subgroup analyses revealed the underlying sources of heterogeneity. Publication bias was observed in the analysis of metastasis. Sensitivity analysis revealed that the results were robust. Our findings indicated that ezrin overexpression was significantly correlated with poor survival and more advanced tumor progression in bone and soft tissue sarcomas, which suggests that ezrin might be a valuable prognostic biomarker and a potential therapeutic target. John Wiley and Sons Inc. 2019-09-03 /pmc/articles/PMC6768105/ /pubmed/31376222 http://dx.doi.org/10.1002/2211-5463.12713 Text en © 2019 The Authors. Published by FEBS Press and John Wiley & Sons Ltd. This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Articles
Wang, Feng
Yu, Tao
Ma, Chengbin
Zhang, Haifei
Zhang, Zhiyu
The clinical prognostic significance of ezrin in patients with bone and soft tissue sarcomas: a meta‐analysis
title The clinical prognostic significance of ezrin in patients with bone and soft tissue sarcomas: a meta‐analysis
title_full The clinical prognostic significance of ezrin in patients with bone and soft tissue sarcomas: a meta‐analysis
title_fullStr The clinical prognostic significance of ezrin in patients with bone and soft tissue sarcomas: a meta‐analysis
title_full_unstemmed The clinical prognostic significance of ezrin in patients with bone and soft tissue sarcomas: a meta‐analysis
title_short The clinical prognostic significance of ezrin in patients with bone and soft tissue sarcomas: a meta‐analysis
title_sort clinical prognostic significance of ezrin in patients with bone and soft tissue sarcomas: a meta‐analysis
topic Research Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6768105/
https://www.ncbi.nlm.nih.gov/pubmed/31376222
http://dx.doi.org/10.1002/2211-5463.12713
work_keys_str_mv AT wangfeng theclinicalprognosticsignificanceofezrininpatientswithboneandsofttissuesarcomasametaanalysis
AT yutao theclinicalprognosticsignificanceofezrininpatientswithboneandsofttissuesarcomasametaanalysis
AT machengbin theclinicalprognosticsignificanceofezrininpatientswithboneandsofttissuesarcomasametaanalysis
AT zhanghaifei theclinicalprognosticsignificanceofezrininpatientswithboneandsofttissuesarcomasametaanalysis
AT zhangzhiyu theclinicalprognosticsignificanceofezrininpatientswithboneandsofttissuesarcomasametaanalysis
AT wangfeng clinicalprognosticsignificanceofezrininpatientswithboneandsofttissuesarcomasametaanalysis
AT yutao clinicalprognosticsignificanceofezrininpatientswithboneandsofttissuesarcomasametaanalysis
AT machengbin clinicalprognosticsignificanceofezrininpatientswithboneandsofttissuesarcomasametaanalysis
AT zhanghaifei clinicalprognosticsignificanceofezrininpatientswithboneandsofttissuesarcomasametaanalysis
AT zhangzhiyu clinicalprognosticsignificanceofezrininpatientswithboneandsofttissuesarcomasametaanalysis